Parenteral replacement therapy with iron dextran or ferumoxytol in patients with iron deficiency
Giampaolo Talamo1, Rintaro Onishi2, Rahul Anand3, Sundeep Bekal1, Joseph Kuruvilla1, Muneer Khan1, Marcelle G. Meseeha1, Kelly L. Wurzler4
1 Hematology/Oncology, Guthrie Robert Packer Hospital, Sayre, PA, 2 Binghamton University, Binghamton, NY, 3 Internal Medicine, and 4 Pharmacy, Guthrie Robert Packer Hospital, Sayre, PA, USA
DOI 10.5414/CP204904
Abstract
Objective: To evaluate the changes in hematological parameters after replacement therapy with either iron dextran or ferumoxytol in patients with iron deficiency.
Materials and methods: We conducted a retrospective review of 246 consecutive patients with iron deficiency treated with a single intravenous (IV) infusion of a fixed dose of 1,025 mg of iron dextran (145 patients) or 1,020 mg of ferumoxytol (101 patients). Laboratory data were collected at baseline and at 2 – 3 months after replacement therapy.
Results: The median hemoglobin (Hb) and ferritin levels pre- and post-iron dextran were 9.5 (95% CI, 9.2 – 10.0) g/dL and 17 (95% CI, 14 – 20) ng/mL, and 12.0 (95% CI, 11.7 – 12.2) g/dL (p < 0.0001) and 123 (95% CI, 98 – 162) ng/mL (p < 0.0001), respectively. The median Hb and ferritin levels pre and post ferumoxytol were 10.4 (95% CI, 9.8 – 10.9) g/dL and 22 (95% CI, 18 – 28) ng/mL, and 12.5 (95% CI, 12.1 – 12.9) g/dL (p < 0.0001) and 129 (95% CI, 90 – 174) ng/mL (p < 0.0001), respectively. No statistically significant difference was observed between iron dextran and ferumoxytol in change of Hb levels, ferritin, transferrin saturation, mean corpuscular volume (MCV), and red cell distribution width (RDW). Transfusion reactions with iron dextran and ferumoxytol were observed in 2 (1.4%) and 3 (3%) patients, respectively (p = 0.65).
Conclusion: In patients with iron deficiency, the change of the hematological parameters after replacement therapy was not statistically different between iron dextran and ferumoxytol. Our data suggests that these two formulations have similar efficacy and safety after the IV administration of equivalent doses.
Author Details
Authors
Departments
- 1 Hematology/Oncology, Guthrie Robert Packer Hospital, Sayre, PA,
- 2 Binghamton University, Binghamton, NY,
- 3 Internal Medicine, and
- 4 Pharmacy, Guthrie Robert Packer Hospital, Sayre, PA, USA
Address
Giampaolo Talamo, MD
Attending Physician
Hematology/Oncology
Guthrie Robert Packer Hospital
One Guthrie Sq, Sayre, PA 18840, USA
Email:
[email protected]
Citation
Giampaolo Talamo, Rintaro Onishi, Rahul Anand, Sundeep Bekal, Joseph Kuruvilla, Muneer Khan, Marcelle G Meseeha, Kelly L Wurzler.Parenteral replacement therapy with iron dextran or ferumoxytol in patients with iron deficiency
. Int J Clin Pharmacol Ther. 2026;
64:
203-
209.
doi: 10.5414/CP204904.
Pubmed:
https://pubmed.ncbi.nlm.nih.gov/41467635/;
PMID: 41467635.